SENDRNA Trademark

Trademark Overview


On Wednesday, January 12, 2022, a trademark application was filed for SENDRNA with the United States Patent and Trademark Office. The USPTO has given the SENDRNA trademark a serial number of 97214928. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 2, 2024. This trademark is owned by Senda Biosciences, Inc.. The SENDRNA trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Biological compound in the form of a molecular complex that acts as a platform for the delivery of RNA-based drugs to biological cells; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies; oligonucleotide compounds for use in the targeted delivery of RNAi therapy; oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intramuscularly, intravenously or subcutaneously for use in targeted pharmaceutical therapies for a wide range of medical purposes

research and development of pharmaceutical products; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections
sendrna

General Information


Serial Number97214928
Word MarkSENDRNA
Filing DateWednesday, January 12, 2022
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 2, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 3, 2022

Trademark Statements


Goods and ServicesBiological compound in the form of a molecular complex that acts as a platform for the delivery of RNA-based drugs to biological cells; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies; oligonucleotide compounds for use in the targeted delivery of RNAi therapy; oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intramuscularly, intravenously or subcutaneously for use in targeted pharmaceutical therapies for a wide range of medical purposes
Goods and Servicesresearch and development of pharmaceutical products; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, January 19, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, January 19, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSenda Biosciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140

Party NameSenda Biosciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140

Trademark Events


Event DateEvent Description
Saturday, January 15, 2022NEW APPLICATION ENTERED
Wednesday, January 19, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, March 30, 2022ASSIGNED TO EXAMINER
Wednesday, March 30, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 13, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 3, 2022PUBLISHED FOR OPPOSITION
Tuesday, May 3, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 24, 2022EXTENSION OF TIME TO OPPOSE RECEIVED
Wednesday, August 24, 2022TEAS POST PUBLICATION AMENDMENT RECEIVED
Friday, September 9, 2022ASSIGNED TO PETITION STAFF
Sunday, September 11, 2022EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Wednesday, September 14, 2022CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Tuesday, October 25, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, April 24, 2023SOU TEAS EXTENSION RECEIVED
Monday, April 24, 2023SOU EXTENSION 1 FILED
Monday, April 24, 2023SOU EXTENSION 1 GRANTED
Wednesday, April 26, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 20, 2023SOU TEAS EXTENSION RECEIVED
Friday, October 20, 2023SOU EXTENSION 2 FILED
Friday, October 20, 2023SOU EXTENSION 2 GRANTED
Tuesday, October 24, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 31, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, January 31, 2024SOU EXTENSION 3 FILED
Wednesday, January 31, 2024SOU EXTENSION 3 GRANTED
Friday, February 2, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 2, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, December 2, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, December 2, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, December 2, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED